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In the last years, thanks to the improvement in the prognosis of cancer patients, a growing attention has been
given to the fertility issues. International guidelines on fertility preservation in cancer patients recommend that
physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease
and/or treatment and their interest in having children after cancer, and help with informed fertility preservation
decisions. As recommended by the American Society of Clinical Oncology and the European Society for Medical
Oncology, sperm cryopreservation and embryo/oocyte cryopreservation are standard strategies for fertility
preservations in male and female patients, respectively; other strategies (e.g. pharmacological protection of the
gonads and gonadal tissue cryopreservation) are considered experimental techniques. However, since then, new
data have become available, and several issues in this field are still controversial and should be addressed by
both patients and their treating physicians.
In April 2015, physicians with expertise in the field of fertility preservation in cancer patients from several
European countries were invited in Genova (Italy) to participate in a workshop on the topic of “cancer and
fertility preservation”. A total of ten controversial issues were discussed at the conference. Experts were asked to
present an up-to-date review of the literature published on these topics and the presentation of own unpublished data
was encouraged. On the basis of the data presented, as well as the expertise of the invited speakers, a total of ten
recommendations were discussed and prepared with the aim to help physicians in counseling their young patients
interested in fertility preservation.
Although there is a great interest in this field, due to the lack of large prospective cohort studies and randomized trials
on these topics, the level of evidence is not higher than 3 for most of the recommendations highlighting the need of
further research efforts in many areas of this field. The participation to the ongoing registries and prospective studies is
crucial to acquire more robust information in order to provide evidence-based recommendations.
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Table 1 Levels of evidence and grades of recommendation
(according to the ESMO Clinical Practice Guidelines for fertility
preservation in cancer patients [11])
Levels of evidence
I Evidence from at least one large randomized, controlled trial of good
methodological quality (low potential for bias) or meta-analyses of
well-conducted randomized trials without heterogeneity
II Small randomized trials or large randomized trials with a suspicion of
bias (lower methodological quality) or meta-analyses of such trials or
of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grade of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs, etc.), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
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Although cancer incidence increases with age and peaks
after the age of 50, thousands of young women and men
are diagnosed with cancer every year [1]. Modern antican-
cer treatments have led to significant reduction in mortal-
ity, but also to an increase in unwanted side effects such
as reduced fertility. Combined with an increased age for
childbearing [2], a higher number of cancer survivors
require fertility preservation to complete their families.
The threat or experience of treatment-related infertility
can lead to psychological distress [3], and many patients are
interested in maintaining fertility and future reproductive
function at the time of cancer diagnosis [4, 5]. Moreover,
fertility concerns may also substantially affect their treat-
ment decisions [6–8]. Thus, great attention to fertility
issues is warranted at the time of cancer diagnosis.
International guidelines recommend that physicians
discuss, as early as possible, with all patients of reproductive
age their risk of infertility from the disease and/or treat-
ment and their interest in having children after cancer, and
help with informed fertility preservation decisions [9–11].
As recommended by the American Society of Clinical
Oncology (ASCO) and the European Society for Medical
Oncology (ESMO), sperm cryopreservation and embryo/
oocyte cryopreservation are standard strategies for fertility
preservation in male and female patients, respectively [10,
11]. Other strategies (e.g. pharmacological protection of
the gonads and gonadal tissue cryopreservation) are still
generally considered experimental techniques [10, 11].
However, new data in this field have become available over
the past few years for consideration. Furthermore, several
issues remain controversial with regard to the safety and
efficacy of fertility preservation strategies in cancer sur-
vivors. In the present manuscript, we summarize and
discuss the up-to-date knowledge on ten controversial
topics in the field of fertility preservation in young patients
with cancer.
Methods
In April 2015, physicians with expertise in the field of fertil-
ity preservation in cancer patients from several European
countries were invited in Genova (Italy) to participate in a
workshop on the topic of “cancer and fertility preservation”.
The invited experts represented different disciplines related
to the topic including oncologists, hematologists, gynecolo-
gists, fertility specialists.
A total of ten controversial issues were focused on at
the conference. Experts were asked to present an up-to-
date review of the literature on these topics. In addition,
the presentation of own unpublished data when available
was encouraged.
On the basis of the data presented, as well as the ex-
pertise of the invited speakers, recommendations sur-
rounding each topic were discussed and prepared withthe aim to help physicians in counseling their young
cancer patients interested in fertility preservation. To
gain a United States (US) perspective, the recommenda-
tions were discussed and reviewed by Dr. Ann H. Par-
tridge, from the Dana-Farber Cancer Institute, Boston
(MA).
To evaluate the levels of evidence and grades of rec-
ommendation, the grading system commonly used in
oncology was chosen (Table 1) [11].
Controversial issues in fertility preservation in cancer
patients
Is there an increased risk of developing breast cancer in
women treated with ovarian stimulating drugs for
infertility?
Elevated blood level of endogenous estrogen are known
to be associated with an increased risk of breast cancer
[12–14]. A large meta-analysis including more than 50
observational studies for a total of 160,000 women, dem-
onstrated a higher risk of having breast cancer (relative
risk [RR] = 1.35; 95 % confidence intervals [CI] 1.21-1.49)
for users of hormone-replacement therapy (HRT) for
5 years or longer [15].
For these reasons, some concerns exist on the safety of
using ovarian stimulating drugs. However, unlike HRT,
characterized by a long lasting exposure to low estro-
gen levels and more robust data on the subsequent risk
of breast cancer with this approach [15], the use of
ovarian stimulating drugs in subfertile patients is associated
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sient and shorter periods but with conflicting results on the
risk of breast neoplasms [16, 17].
Recently, a systematic review and meta-analysis of co-
hort studies evaluated the association between hormonal
infertility treatments and risk of developing breast cancer
[18]. A total of 20 studies with 207,914 women exposed to
hormonal treatments for infertility and 2,347 incident
cases of breast cancer were included. Overall, no increased
risk was detected with the use of hormonal treatments for
infertility (summary RR [SRR] = 1.05; 95 % CI 0.96-1.14)
but a significant heterogeneity among studies was detected
(I2 = 59 %; P = 0.001) [18]. In subgroup analyses, when
considering only the seven studies with the in vitro
fertilization (IVF) procedure, no increase in breast cancer
risk was detected (SRR = 0.96; 95 % CI 0.81-1.14). On the
contrary, a moderately increased breast cancer risk was
observed in the three studies where women were treated
outside IVF protocols (SRR = 1.26; 95 % CI 1.06-1.50):
however, to note, in these studies patients were enrolled
before 1980. Overall, the meta-analysis did not support
the hypothesis that hormonal treatments for infertility are
associated with an increased breast cancer risk [18].
Recently, a large US cohort study reported reassuring
results about the long-term effects of ovarian stimulating
drugs with clomiphene or gonadotropins [19]. After a
median follow up of 30 years, out of 9,892 women evalu-
ated for infertility, 749 developed breast cancer. Ever use of
clomiphene citrate was not associated with risk (hazard ra-
tio [HR] = 1.05; 95 % CI 0.90-1.22). However, a significantly
elevated risk was observed for patients who received both a
high cumulative dose (i.e. ≥ 2251 mg) and multiple cycles
(i.e. ≥ 6 cycles), with an HR of 1.27 (95 % CI 1.02-1.59).
Ever use of gonadotropins was not significantly associated
with the risk of developing breast cancer (HR = 1.14; 95 %
CI 0.89-1.44), with no trends according to dosage, number
of cycles, or age at first use [19].
Despite these encouraging findings for infertile women
who wish to undergo IVF procedures, caution is needed
because it is difficult to assess the risk of breast cancer
in this setting. In fact, several factors (e.g. pregnancy, in-
fertility itself and the use of different therapeutic proto-
cols) might impact study results due to their direct or
indirect effect on the risk of developing breast cancer
[18]. Moreover, the evidence derived from observational
studies have possible biases, including selection bias and
ascertainment bias [18].
Recommendation 1 Ovarian stimulating drugs with
standard treatment protocols may be administered in
subfertile/infertile women without increasing the risk of
developing breast cancer (III, B). The long-term use of
clomiphene outside the current limited indications (i.e.
first-line therapy of WHO Group II anovulatory infertility)should be discouraged because of a possible increase in
breast cancer risk (III, B).Should pregnancy after cancer be considered safe?
A considerable proportion of cancer patients of childbear-
ing age (approximately 50 %) desire pregnancy at the time
of cancer diagnosis [20]. However, cancer survivors have
lower fecundity rates than the general population. A large
population-based matched cohort study showed that des-
pite an overall lower pregnancy rate in cancer survivors
(23 % of men and 13 % of female) than in controls from the
general population (32 % of men and 22 % of female), male
survivors initiated pregnancies in a higher proportion
(HR = 0.74; 95 % CI 0.71-0.78) than female survivors
(HR = 0.61; 95 % CI 0.58-0.64) [21]. Patients with malignant
melanoma or thyroid cancer showed a similar pregnancy
rate as compared to the controls: a possible reason is that
the treatments required for these diseases when caught at
early stages have no major negative impact on patients’ fer-
tility [21]. Survivors of ovarian cancer, testicular cancer, and
Hodgkin lymphoma diagnosed in men, showed increasing
pregnancy rates over time [21]. On the other hand, survi-
vors of leukemia, cervical cancer or breast tumors showed
the lowest rates for subsequent pregnancies [21].
Breast cancer patients have the lowest pregnancy rate
among cancer survivors, with an overall 67 % reduction
in the chance of having babies after cancer treatment as
compared to the general population [21]. This observa-
tion reflects not only the damage to ovarian reserve due
to the gonadotoxic treatments required, but also patient
and provider concerns related to a possible negative im-
pact of pregnancy on the evolution of breast cancer, be-
ing a hormonally driven disease. However, available data
suggest that pregnancy after breast cancer does not
negatively impact patients’ prognosis, irrespectively of the
hormone receptor status of the tumor. A meta-analysis of
14 retrospective control-matched studies showed that
breast cancer patients who became pregnant following
diagnosis and treatment had a 41 % reduced risk of death
compared to women who did not get pregnant (pooled RR
[PRR] = 0.59; 95 % CI 0.50-0.70) [22]. While these results
could be partially confounded by selection bias or the
healthy mother effect, and lack of information in hormone
receptor positive patients, a more recent multicenter retro-
spective cohort study adjusting for this effect confirmed
safety of pregnancy after breast cancer even in patients with
endocrine-sensitive disease [23]. This study showed no
difference in disease-free survival (DFS) between pregnant
and non-pregnant patients in the estrogen-receptor posi-
tive group (HR = 0.91; 95 % CI 0.67-1.24), nor in the
estrogen-receptor negative cohort (HR = 0.75; 95 % CI
0.51-1.08) [23]. Importantly, no impact of abortion on pa-
tient outcome was observed either [23].
Lambertini et al. BMC Medicine  (2016) 14:1 Page 4 of 16In addition, the possible occurrence of congenital ab-
normalities and the potential obstetric and birth compli-
cations are two main concerns for young cancer
survivors who want to reproduce after anticancer treat-
ment. In general, reseach has revealed that the neonatal
outcomes in both male and female survivors are not dif-
ferent from those of the general population [24–29].
However, high induced abortion rates have been ob-
served in patients who became pregnant after breast
cancer diagnosis reaching as high as 30 % [23, 30, 31].
Moreover, in breast cancer survivors, a higher incidence
of birth complications (i.e. caesarean section, preterm
birth, babies with low birth weight) was observed in pa-
tients as compared to controls [25]. Women undergoing
pelvic irradiation might experience uterine damage with
a possible increased risk of miscarriage, preterm birth,
and low birth weight [32]. For all these reasons, a close
monitoring of pregnancy in such patients is recom-
mended [33].
To date, pregnancy after cancer should be considered
safe and not be discouraged in general [11]. However, it
is not clear yet the ideal interval to wait between the end
of anticancer treatments and conception. Two main
interval issues should be considered: to wait until the
patient is at lower risk of relapse, and to wait until the
anticancer therapy is out of a patient’s system (i.e. up to
3–6 months following the last administered dose) [11].
According to expert opinion, the timing should be “per-
sonalized” taking into account age and ovarian reserve
of the patient, previous treatments and time of their
completion, and individual risk of relapse [11]. In
breast cancer patients with hormone receptor-positive
disease, the need for adjuvant endocrine therapy is an-
other important issue to be considered: its use for up
to 5–10 years can lead to a natural decline in ovarian
reserve due to age, thus hindering the chances of future
pregnancies. An international prospective study with
the aim to evaluate the feasibility and safety of a tempor-
ary interruption of endocrine therapy to allow pregnancy
is ongoing (the POSITIVE study) [34].
Recommendation 2 Pregnancy in cancer survivors,
after adequate treatment and follow up, should not be
discouraged, including among patients with endocrine-
sensitive breast cancer (III, A).
Should all patients be referred to a fertility unit before
initiating anticancer treatments?
Anticancer treatments (surgery, radiotherapy, cytotoxic
chemotherapy and endocrine therapy) may affect male
and female fertility transiently or permanently [9].
Surgery can have a direct impact on patients’ fertility
causing anatomic or vascular problems (e.g. retrograde
ejaculation or impaired ejaculation, changes to theuterus, cervix or vagina) [9]. Chemotherapy and radio-
therapy have a direct gonadotoxic effect by destroying
ovarian follicles that constitute woman’s ovarian re-
serve [35–37] and by compromising sperm number,
motility, morphology, and DNA integrity in male pa-
tients [9]. Finally, endocrine treatments used in breast
cancer patients have both a direct and indirect effect
on fertility and ovarian function: the direct effect, oc-
curring during treatment only, is due to an impairment
in ovulatory and endometrial functions, while the indirect
effect is associated with the delay to conception that
allows ovarian aging.
As recommended by major international guidelines on
fertility preservation in cancer patients, clinicians should
discuss with their patients the potential impact of an-
ticancer treatment on fertility as early as possible and
help with fertility preservation decisions among at-risk
survivors interested in having children after cancer
[10, 11, 38].
However, the rate of treatment-related infertility is
variable and depends on several factors: type of cancer,
age of the patient, history of previous treatment for infer-
tility and comorbidities, type and dose of the chemother-
apy regimen used, method of administration (oral versus
intravenous), size and location of the radiation field and
its dose, need of adjuvant endocrine therapy (Table 2)
[9, 39]. Specifically, type of treatment and patients’ age
are the most important factors to be taken into account
when counseling the patients [40].
Onco-fertility counseling should be individualized,
discussing both the absolute benefits of the proposed
anticancer treatment (e.g. adjuvant chemotherapy or long
duration of endocrine therapy in young breast cancer pa-
tients at low risk of recurrence) and the risk of infertility
for each individual (based on patient-related factors [age,
comorbidities, ovarian reserve in women [41]] and the
sterilizing potential of the treatment proposed). In some
situations the risk of treatment-related infertility can be
difficult to estimate due to limited available data; however,
providers should not overestimate the risk of treatment-
related infertility for cancer patients and some of them
(e.g. very young patients undergoing treatment at low risk
of infertility) can be reassured that they will not likely re-
quire the help of a fertility clinic after cancer treatment
[42]. On the other hand, the perception of a high risk for
infertility is individual and the patients’ own wishes should
also be taken into account. Further, to note that even with
regimens associated with low risk of gonadotoxicity
(e.g. doxorubicin,bleomycin,vinblastine,dacarbazine [ABVD]
in Hodgkin lymphoma patients), nonetheless ovarian
reserve is reduced and fertility may be impaired, particu-
larly when pregnancy is delayed [43, 44]. Moreover, some
patients may relapse and subsequently become candidates
for different types of chemotherapy and at higher doses
Table 2 Risk of treatment-related infertility with the main anticancer therapies (modified from the original [9])
Degree of risk Type of anticancer treatment
Women Men
High risk
(>80 % risk of permanent amenorrhea in women;
prolonged azoospermia in men)
-HSC transplantation with cyclophosphamide/
TBI or cyclophosphamide/busulfan
-External beam radiation to a field that includes
the ovaries
-CMF, CEF, CAF, TAC x 6 cycles in women
≥ 40 years
-Radiation > 2.5 Gy to testis
-Chlorambucil (1.4 g/m2)
-Cyclophosphamide (19 g/m2)
-Procarbazine (4 g/m2)
-Melphalan (140 mg/m2)
-Cisplatin (500 mg/m2)
-BCNU (1 g/m2) and CCNU (500 mg/m2)
Intermediate risk
(40 % - 60 % risk of permanent amenorrhea in women;
likelihood of azoospermia in men especially when given
with other sterilizing agents)
-BEACOPP
-CMF, CEF, CAF, TAC x 6 cycles in women
age 30–39
-AC x 4 cycles in women≥ 40 years
-AC or EC x 4 → Taxanes
-Busulfan (600 mg/kg)
-Ifosfamide (42 g/m2)
-BCNU (300 mg/m2)
-Nitrogen mustard
-Actinomycin D
Low risk
(<20 % risk of permanent amenorrhea in women; only
temporary reductions in sperm counts in men especially
when not given with other sterilizing agents)
-ABVD in women≥ 32 years
-CHOP x 4–6 cycles
-CVP
-AML therapy (anthracycline/cytarabine)
-ALL therapy (multi-agent)
-CMF, CEF, CAF, TAC x 6 cycles in women
≤ 30 years
-AC x 4 cycles in women≤ 40 years
-Carboplatin (2 g/m2)
-Doxorubicin (770 mg/m2)
-Thiotepa (400 mg/m2)
-Cytosine arabinoside (1 g/m2)
-Vinblastine (50 g/m2)
-Vincristine (8 g/m2)
Very low or no risk
(risk of permanent amenorrhea in women; temporary
reductions in sperm count in men but additive effects
are possible)
-ABVD in women < 32 years
-Methotrexate
-Fluorouracil
-Vincristine
-Tamoxifen
-Amsacrine
-Bleomycin
-Dacarbazine
-Daunorubicin
-Epirubicin
-Etoposide
-Fludarabine
-Fluorouracil
−6-mercaptopurine
-Methotrexate
-Mitoxantrone,
-Thioguanine
-Prednisone
-Interferon-α
Unknown risk
(risk of permanent amenorrhea in women; effect on
sperm production in men)
-Monoclonal antibodies (trastuzumab,
bevacizumab, cetuximab)
-Tyrosine kinase inhibitors
(erlotinib, imatinib)
-Oxaliplatin
-Irinotecan
-Monoclonal antibodies (trastuzumab,
bevacizumab, cetuximab)
-Tyrosine kinase inhibitors
(erlotinib, imatinib)
-Taxanes
HSC hematopoietic stem cell, TBI total body irradiation, CMF cyclophosphamide, methotrexate, fluorouracil, CEF cyclophosphamide, epirubicin, fluorouracil,
CAF cyclophosphamide, doxorubicin, fluorouracil, TAC docetaxel, doxorubicin, cyclophosphamide, BEACOPP doxorubicin, belomycin, vincristine, etoposide,
cyclophosphamide, procarbazine, BCNU carmustine, CCNU lomustine, AC doxorubicin, cyclophosphamide, EC epirubicin, cyclophosphamide, ABVD doxorubicin,
bleomycin, vinblastin, dacarbazine, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, CVP cyclophosphamide, vincristine, prednisone, AML acute
myeloid leukemia, ALL acute lymphocitic leukemia
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function.
Recommendation 3 All patients with potential interest
in keeping their fertility should be referred to fertility
unit for adequate determination of risk of infertility,
chances of future conception and how to proactively
preserve it (V, A). However, some cancer patients will
not require the help of a fertility clinic after cancer treat-
ment (V, B). Since several patient- and treatment-related
factors are associated with the risk of developing infertil-
ity, the oncofertility counseling should be tailored to the
individual patient (V, A).Are gamete and embryo cryopreservation strategies
accepted by young cancer patients, when available and
accessible?
Despite a growing amount of evidence suggesting that
fertility issues are of great importance for young cancer
patients, how many are counseled and offered these
procedures is not well documented. In men, sperm
cryopreservation is an effective strategy for fertility
preservation: it does not require major delays in treat-
ment initiation and can be easily performed in many
centers [45]. In women, access to standard strategies
(oocytes/embryos cryopreservation) may be more diffi-
cult because of urgent need for treatment, and lack of a
Lambertini et al. BMC Medicine  (2016) 14:1 Page 6 of 16well-organized interaction between oncology and fertil-
ity units.
The percentage of women who choose to undergo the
available fertility preservation options after fertility coun-
seling varies from 2 % to over 50 % [46, 47]. In a recent
large study conducted in breast cancer patients, only
10 % of women took active steps to reduce their chance
of infertility (7 % underwent embryo cryopreservation,
1 % oocyte cryopreservation and 3 % accepted the ad-
ministration of luteinizing hormone-releasing hormone
analogs [LHRHa]); however, an increasing trend over
time in the proportion of patients who pursued fertility
preservation strategies was observed (from 5 % in 2006
to 15 % in 2012) [7].
In a recent prospective study conducted in 7 large
Italian Institutions, the rate of application of cryopreserva-
tion techniques was evaluated in male and female cancer
patients who underwent onco-fertility counseling over a
period of 2 years (unpublished observations). Out of 510
men, 507 (99.4 %) cryopreserved at least one semen sam-
ple, and 88 (17.4 %) patients underwent two or more
sperm collections. Out of 491 women, 132 (26.8 %) were
considered not eligible for cryopreservation strategies (i.e.
due to need to start chemotherapy immediately, inad-
equate ovarian reserve, high risk of complication or use of
treatments with a low risk of gonadotoxicity). Among eli-
gible patients, 66.6 % underwent cryopreservation tech-
niques to preserve fertility (Table 3). The lack of
discussion of fertility issues between patients and physi-
cians [47–49], and inadequate access to the strategies,
are possible explanations of these findings [50, 51].
Greater effort is needed to improve both the communi-
cation between patients and physicians about fertility risks
and preservation options, and the collaboration among
oncologists and fertility specialists to give patients the
opportunity to undergo well-timed and complete repro-
ductive counseling. Further research is needed to better
understand the preferences of patients among the available
strategies for fertility preservation: this information would
have great importance from a public health perspective and
for resource allocation standpoint. Moreover, a better un-
derstanding of the factors that influence patients’ choice
would help physicians to improve the quality of their fertil-
ity counseling.Table 3 The choices regarding fertility preservation of female cance
Type of cancer n (%) Eligible for cryopreservation
strategies
n (%)
Declin
strate
n (%)
Breast 281 (57.2) 186 (66.2) 76 (40
Hematologic disease 123 (25.1) 98 (79.7) 27 (27
Others 87 (17.7) 75 (86.2) 17 (22
Total 491 (100) 359 (73.1) 120 (3Recommendation 4 In men, sperm cryopreservation is
an easily accessible and widely available option in more
than 95 % of patients and should be encouraged for those
who want to preserve fertility (III, A). On the contrary,
from 2 % to 65 % of women undergo one of the available
cryopreservation options: oncologists should discuss with
them the fertility issues and secure proper counseling in
appropriate centers prior to cancer treatment (IV, A).
Which are the results and the safety of assisted
reproduction technologies (ART) in male patients previously
treated with chemotherapy?
Anticancer treatments (i.e. chemotherapy and radiotherapy)
can damage the germinal epithelium in men resulting in
oligozoospermia or azoospermia: in fact, a large proportion
of patients treated for cancer have lower sperm concentra-
tions than matched controls [9]. Currently, no strategies for
medical protection of the germinal epithelium are available.
Further, prepubertal age cannot be considered a protective
factor from gonadotoxic insults. Data suggest that can-
cer itself can influence spermatogenesis [52]. However,
no correlation between semen alterations and cancer stage
or associated symptoms has been detected [53, 54].
Sperm cryopreservation before gonadotoxic therapies
is the standard strategy for fertility preservation in adult
men [10, 11]. A large proportion of treated patients
maintains or regains a level of spermatogenesis adequate
to obtain spontaneous conception [55]. However, male
cancer survivors who don’t recover spermatogenesis nor
had their semen cryopreserved before cytotoxic therapy
may need ART, and specifically intracytoplasmatic sperm
injection (ICSI), in order to reproduce. Therefore, when
considering the safety of conception after radiotherapy
and/or chemotherapy, there are three different scenarios:
a) spontaneous conception in patients with continued
post radiotherapy/chemotherapy spermatogenesis; b) ART
conception with normal or abnormal cryopreserved sperm;
c) ART conception with post radiotherapy/chemotherapy
residual spermatogenesis (ICSI particularly).
The limited available data on fatherhood after cancer
are related to offspring from spontaneous conceptions or
from IVF/ICSI with spermatozoa cryopreserved before the
initiation of anticancer treatments. Until recently, none of
the research reported an increased rate of congenitalr patients enrolled in the Italian study
ed cryopreservation
gies
Accepted oocyte
cryopreservation
n (%)
Accepted ovarian tissue
cryopreservation
n (%)
.9) 103 (55.4) 7 (3.8)
.6) 50 (51.0) 21 (21.4)
.7) 38 (50.7) 20 (26.7)
3.4) 191 (53.2) 48 (13.4)
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treated patients with subsequent spontaneous conceptions
[52]. In a large retrospective cohort analysis of validated
cases of congenital anomalies among 4,699 children of
1,128 male and 1,627 female cancer survivors an anomaly
prevalence of 2.7 % has been found in the offspring of can-
cer survivors, similar to the prevalence in the general
population of the US [56]. Conceptions from ART treat-
ments were excluded from the study as the use of donor
could not be determined [56]. For children whose fathers
were exposed to radiation or alkylating agents versus nei-
ther, the prevalence of anomalies was 1.9 % versus 1.7 %
(p = 0.79). Testicular radiation dose (mean 0.48 Gray) was
not related to the risk of congenital anomalies (odds ratio
[OR] = 1.01; 95 % 0.36-2.83 for 0.50+ Gray). Treatment
with alkylating agents was not significantly associated with
anomalies in the children of male survivors [56].
Conflicting results were demonstrated in a cohort study
from Danish and Swedish registries, regarding 8,670 babies
with a paternal history of cancer: a total of 8,162 children
were conceived naturally and 508 were conceived using
ART (i.e. IVF or ICSI) [57]. Overall, the offspring of male
cancer survivors were more likely to have major congenital
abnormalities than those of fathers without cancer
(RR = 1.17; 95 % CI 1.05-1.31), with some differences
between the different types of cancer. Although not
significant, a link between paternal history of cancer and
risk of major congenital abnormalities was suggested in
children born within 2 years of their father’s cancer diag-
nosis (RR = 1.27; 95 % CI 0.89-1.80) [57]. The association
between paternal history of cancer and risk of congenital
abnormalities was not modified by the mode of concep-
tion, natural conception (RR = 1.17; 95 % CI 1.04-1.31) or
ART (RR = 1.22; 95 % CI 0.80-1.87). Out of the 205 chil-
dren conceived through ART with available information,
137 (55 %) were conceived using fresh post-treatment
semen and 68 (27 %) using sperm cryopreserved before
treatment initiation. The same prevalence of major con-
genital abnormalities were observed in children conceived
using fresh post-treatment semen (4.4 %) or those born
using cryopreserved pre-treatment spermatozoa (4.4 %)
[57]. Although limited by small numbers, this finding sug-
gests the possibility that the increase in abnormalities
could be due to some factors unrelated to anticancer
therapies.
The efficacy of ART in patients treated for cancer
seems to be good. In a comparative study of male cancer
survivors treated with ICSI using cryopreserved sperm,
which were compared to non-cancer infertile males that
had previously frozen sperm, the live birth rate using
ART was similar in the two groups [58].
To our knowledge, only two studies have been published
describing the offspring of patients undergoing ART con-
ceptions with the use of fresh ejaculated or testicular semenafter treatment [59, 60]. Ping and colleagues described the
fertility outcome in 117 testicular cancer survivors [59].
Out of 21 patients who banked their semen before starting
chemotherapy, 19 achieved conception by ART (11 patients
used fresh semen and 8 used cryopreserved semen) [59]. A
total of 37 healthy babies were conceived with no congeni-
tal malformations or childhood malignancies [59]. Recently,
a large US experience reported the successful treatment
of post-chemotherapy azoospermia with the use of
microsurgical testicular sperm extraction: a total of 73
post-chemotherapy azoospermic patients who under-
went ART were included [60]. Sperm was retrieved in
37 % of patients; fertilization rate by ICSI (per injected
oocyte) was 57.1 %, with a reported clinical pregnancy
rate of 50 % and an overall live birth rate of 42 %. A
total of 15 deliveries were described, with 5 twin births.
The 20 children were healthy with no apparent abnormal-
ities; no details on obstetric outcome were reported [60].
In a recent large population-based study on the out-
comes of progeny born after ART in the general popula-
tion, there was no increase in the overall risk of cancer
among British children born after assisted conception
during the 17-year study period [61]. Increased risks of
hepatoblastoma and rhabdomyosarcoma were detected,
but the absolute risks were small [61].
Recommendation 5 Paucity of data is available on
fatherhood after cancer. Although most of the published
data are reassuring, some recent conflicting results
suggest a potential increased risk of birth defects particu-
larly among the children born closer to a paternal cancer
diagnosis, and caution should be taken in counseling these
patients (V, B for discussion with patients); data on
children conceived after ART are too scarce to draw any
conclusion although in the general population, available
evidence for the outcomes of progeny after ART suggests
safety of the techniques themselves (V, B for discussion
with patients).
Is it safe to perform a controlled ovarian stimulation (COS)
in female cancer patients?
Different protocols with different preparations and dosages,
are available in standard ART for oocyte or embryo cryo-
preservation [62]. Two safety issues should be considered
for COS in cancer patients: a possible delay in cancer treat-
ment initiation (the 2-week duration of standard proto-
cols), and a possible negative impact of ovarian
stimulation on the prognosis of patients with hormone-
responsive tumors in particular.
For many diseases, delays of 2 weeks prior to anti-
neoplastic therapy are not possible (e.g. acute leukemia).
However, even in the setting of adjuvant therapy, con-
cerns arise regarding timing of therapy. In early stage
breast cancer, evidence suggests that the earlier adjuvant
Lambertini et al. BMC Medicine  (2016) 14:1 Page 8 of 16chemotherapy is administered, in general, the better pa-
tients’ outcome is obtained [63]. Thus, efforts have been
made to limit delays to preserve fertility in such settings.
In recent years, random stimulation protocols inducing
luteolysis have been adopted to allow to start COS prac-
tically anytime during the menstrual cycle without hav-
ing to wait until the follicular phase [64], but even these
protocols require at least 2 weeks of treatment, during
which time cancer therapy must be delayed. Preliminary
experiences with these “random-start protocols” showed
promising results in terms of oocyte recovery and ma-
turity rate (Table 4) [65–73].
The risk of ovarian hyperstimulation syndrome (OHSS),
a severe complication of COS, should be taken into ac-
count, particularly in young patients with high ovarian re-
serve. In these cases, triggering ovulation with LHRHa
instead of human chorionic gonadotropin (HCG) has been
proven to significantly reduce the occurrence of OHSS, a
complication that may also further delay the start of anti-
cancer treatments [74].
The short-term exposure to high estrogen levels due
to the COS is an important safety concern in patients
with breast cancer. For this reason alternative protocols
for ovarian stimulation with the use of tamoxifen [75] or
letrozole [76] have been developed. In these relatively
small studies, no negative consequence on the quality of
the oocytes and embryos collected has been observed
[75, 77] and pregnancy rates have been similar to those
expected in a noncancer population undergoing IVF
[78]. The largest prospective analysis with the use of
cryopreservation strategies in breast cancer patients re-
ported the safety of a COS with the use of letrozole in
79 women who were compared with 136 patients not
undergoing any fertility-preserving procedures serving as
controls [79]. After a median follow up of 23.4 months
post-chemotherapy, no difference in relapse-free survival
was observed among the two groups (HR = 0.56; 95 % CI
0.17-1.9; P = 0.36) [79]. Recently, updated results of theTable 4 Published experiences with “random-start protocols”
Author No. patients No. of retrieved oocytes No. of cry
Von Wolff et al. [65] 12 10.0 ± 5.7 NR
Michaan et al. [66] 22 8.8 ± 6.0 5.4 ± 4.5
Bedoschi et al. [67] 2 12 7
Sonmezer et al. [68] 3 9 - 17 7 - 10
Maman et al. [69] 5 12.8 ± 8.4 6.4 ± 6.6
Nayak et al. [70] 4 6 - 30 5 - 20
Cakmak H et al. [71] 35 9.9 (7.7 – 12.7) NR
Buendgen NK et al. [72] 10 8.8 (SD: 5.1) NR
Keskin U et al. [73] 3 4 - 16 3 - 9
NR not reported, SD standard deviationstudy, including a larger sample size (338 patients, 120
women undergoing COS and 218 controls) with a longer
median follow up (4.9 years), confirmed the safety of the
procedure [80]. Safety and feasibility of performing two
consecutive COS with the use of letrozole to increase
the oocyte/embryo yield for fertility preservation has also
been reported [81]. However, further research in this filed
is needed on larger series to confirm these results.
To avoid the need for COS, cryopreservation of imma-
ture oocyte or of oocytes matured in vitro are under clinical
development [82, 83]. With these techniques, oocytes are
collected without hormonal stimulation or with a short
stimulation lasting 3–5 days; the immature oocytes col-
lected can be then cryopreserved after maturation in vitro
or cryopreserved at the immature stage and then matured
in vitro after thaw before insemination. So far, only one
child was born in a cancer patient in whom the imma-
ture oocytes were collected prior to gonadotoxic treat-
ment [84]. These strategies should be considered still
experimental.
To date, only one study has reported the safety of per-
forming ART following anticancer treatments for breast
cancer treatment [85]. The authors evaluated the sur-
vival outcomes of a cohort of 198 patients who became
pregnant after breast cancer diagnosis and treatment of
whom 25 women underwent ART resulting in 36 preg-
nancies [85]. A total of 37 ART cycles were performed:
13 oocyte donation, 13 ovarian stimulation for IVF, and
11 ovulation induction. Patients who underwent ART
tended to have more favorable characteristics (e.g. higher
percentage of estrogen receptor positive disease, low
grade tumor and node negative status) [85]. At a median
follow up of 50 months, no difference in DFS and overall
survival has been observed between patients with spon-
taneous pregnancies and those who underwent ART
procedures [85]. However, more data are needed to con-
firm the safety of performing a COS in patients with
prior diagnosis and treatment of breast cancer.opreserved oocytes/embryos Maturation rate (%) Fertilization rate (%)
80.4 75.6
NR NR
70.0 83.3
58.8 – 77.7 69.2 – 87.5
48.6 ± 18.3 69.2 ± 47.4
NR 93.3 – 100
67 (59 – 76) 87 (72–100)
NR 63.6 (SD: 32.9)
NR 75
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the safety of a COS in cancer patients (III, B). “Random-
start protocols” can be employed to avoid delays in anti-
cancer treatment initiation (III, B). LHRHa ovulation trig-
gering should be adopted in patients at moderate-high
risk for OHSS (I, A). Letrozole (or tamoxifen) should be
incorporated in the protocol for COS in cancer patients
with hormone-responsive tumors (III, B).
Which method for cryopreservation of embryos or oocytes
should be used and what should we expect from the use of
this strategy in female cancer patients?
Embryo cryopreservation and oocyte cryopreservation
are standard strategies for fertility preservation in female
cancer patients [10, 11]. In countries where embryo freez-
ing is prohibited by law (e.g. Italy), oocyte cryostorage is the
only applicable non-experimental technology.
Two different methods for embryo or oocyte cryopreser-
vation are currently available: slow freezing and vitrification
[86]. Slow freezing procedure has been the first procedure
to be developed: with this method, eggs are gradually frozen
with low concentration of cryoprotectant agents, thus min-
imizing both structural damages and intracellular formation
of ice [87]. Vitrification uses higher concentrations of cryo-
protectants and an ultra-quick cooling is performed to
avoid toxicity and to reduce the transitional stage; egg sur-
vival and fertilization rates with vitrification are expected to
be higher, since the structural damage due to the formation
of ice crystals is avoided [88]. In a recent Cochrane meta-
analysis of two studies, vitrification showed a higher clinical
pregnancy rate than slow freezing (RR = 3.86, 95 % CI 1.63-
9.11) and better results in terms of oocyte survival rate,
fertilization rate and embryo quality [89]. However, no in-
formation on live birth rates was reported. In experienced
laboratories, results with vitrification may be similar to
those obtained with fresh eggs but success rates are still
highly operator-dependent [90]. Irrespective of which
method is used, the success rates are best in women
under 36 years, although success has been reported up
to age 44 with vitrification [91].
In Italy, due to the legal restrictions limiting the use of
embryo cryopreservation, an increasing trend toward the
use of oocyte freezing has been shown since 2004. Using
data from the Italian Registry of ART in the period
2007–2011, Levi Setti and colleagues showed an increas-
ing use of vitrification in infertile couples and by 2010
vitrification became the most applied technique [92].
The success of oocyte cryopreservation with slow freez-
ing and vitrification were then retrospectively compared,
confirming a statistically significant higher performance
of vitrification than slow freezing, although not as high
as with fresh cycles [92].
Most of the available data on pregnancies obtained with
thawing of embryos or oocytes derive from the infertilenon-oncologic population. Pregnancy rate after embryo
thawing is strongly dependent on age, ranging from over
40 % in women younger than 35 years to less than 20 % in
women over 40 years [93]. Similar results in experienced
hands have been shown after oocyte cryopreservation
[94, 95]. The number of oocytes or embryos stored is
another factor that strongly impacts on the outcomes.
Cancer patients might have a weaker response to COS
[96]: a retrospective observational study reported a lower
number of retrieved oocytes in cancer patients as com-
pared to a historical control group of age-matched women
who underwent ART [97].
As a matter of fact, many issues should be considered
when analyzing ovarian response to COS in cancer patients,
such as the particular protocols used (i.e. “random-start
protocols” to avoid the delay in treatment initiation, or the
use of tamoxifen or letrozole in patients with hormone sen-
sitive diseases to reduce the risk of the exposure to the high
estradiol levels during COS) and/or the presence of a pos-
sible underlying reduced ovarian reserve (e.g. patients with
BRCA 1–2 mutations or due to concurrent illness) [98, 99].
To increase the oocyte yield for fertility preservation,
it has been proposed to perform two consecutive ovarian
stimulation cycles [81]. However, this approach is not
feasible in many cancer settings due to the delay it
would necessitate in starting treatment.
Very limited data are available on pregnancy rates with
thawed oocytes or embryos in cancer patients. To date,
a total of 8 deliveries have been reported after oocyte
warming in the oncologic population [100]. Recently,
out of 357 patients who had their oocytes cryopreserved
after cancer diagnosis, 11 cancer survivors (8 with breast
cancer, 1 with Hodgkin lymphoma, 1 with endometrial
adenocarcinoma, and 1 with thyroid cancer) returned for
ART [101]. In this cohort, a total of 4 pregnancies were
achieved and delivered at term after warming vitrified
oocytes with no major or minor malformations; the deliv-
ery rate per cycle was calculated to be 36.6 % [101]. Even
more recently, Oktay and colleagues provided the preg-
nancy and fertility preservation outcomes in a cohort of
131 breast cancer patients who had previously undergone
COH with letrozole for embryo cryopreservation [78]. A
total of 33 women underwent 40 attempts to transfer
embryos obtaining 18 pregnancies and 25 live births
[78]. Pregnancy rates were comparable to those expected
in the general noncancer population undergoing IVF [78].Recommendation 7 Embryo and oocyte cryopreservation
are standard options for fertility preservation (III, B). Vitri-
fication showed a better performance than slow freezing
(II, B). During oncofertility counseling, patients should be
aware that data on the success of these strategies derive
from infertile women in general and that a different
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cancer patients (IV, B).
Is there any best candidate for ovarian tissue
cryopreservation?
Ovarian tissue cryopreservation has been proven to be
an effective, yet still experimental, technique to preserve
fertility in patients undergoing gonadotoxic therapies
[10, 11]. Following re-implantation of ovarian tissue, a
successful recovery of ovarian function is expected in
almost all cases within 3 to 6 months, with possible
sustained longevity of function of the transplanted tissue
[102, 103]. To date, a total of 40 live births have been re-
ported in cancer patients after transplantation of frozen/
thawed ovarian tissue [104]. It is basically impossible
to calculate a precise pregnancy rate for transplantation of
cryopreserved ovarian tissue until a large cohort of patients
have had all their tissue transplanted [105]. Combining 80
cases from 4 fertility centers, the pregnancy rate (i.e. ratio
between the number of women who conceived and the
number of transplanted women) with the use of this tech-
nique was 25 % [106–109]. Overall, the pregnancy rate with
the use of cryopreservation of ovarian tissue seems to
be increasing [105].
Although ovarian tissue cryopreservation is still an
experimental strategy, it might be proposed to selected
patients. In particular, this method is the only available
option to preserve fertility in prepubertal girls who are
candidates to gonadotoxic therapies [40].
A major advantage of this technique over oocyte or
embryo cryopreservation is that only few days are required
for its application: tissue retrieval can be performed by
laparoscopy, which can be planned shortly after cancer
diagnosis, or during a laparotomy if needed for oncologic
therapies. This technique can be performed at any time of
the menstrual cycle and does not require hormonal stimu-
lation. For these reasons, cryopreservation of ovarian tissue
can be proposed to selected patients who cannot delay the
initiation of anticancer treatments [110].
Another promising indication of ovarian cortex cryo-
preservation is the situation in which patients have already
received chemotherapy. Mature or immature egg collec-
tion is not recommended in patients who have received
recent chemotherapy, owing to possible decreased or no
response to ovarian stimulation, genetically abnormal
oocytes, and deleterious effects on reproductive outcome
(i.e. high abortion and malformation rates), as suggested
by animal studies [111, 112]. On the contrary, the collec-
tion of ovarian tissue may be successfully performed after
a few cycles of chemotherapy due to the fact that a sub-
stantial number of primordial follicles will still survive and
be present in cortical tissue [113].
The success of ovarian tissue cryopreservation is strongly
dependent upon the patient’s ovarian reserve. For thisreason, patients over 40 years or with reduced ovarian
reserve are not good candidates [114]. Furthermore, a
potential risk of reintroducing malignant cells when the
tissue is re-implanted should be considered [115–117].
Therefore, patients diagnosed with cancer with a high
risk of malignant contamination to the ovaries (e.g. ag-
gressive hematologic malignancies) and with no reliable
molecular markers for a pre-transplantation examination
may be not eligible for ovarian tissue auto-transplantation
[118]. Finally, it should be specified that the possibility to
reduce ovarian reserve with ovarian cortex biopsy has not
been well studied to date.
Recommendation 8 The best candidates for ovarian tissue
cryopreservation are prepubertal girls (III, A). The
technique may also be proposed to patients scheduled
for treatments with a high risk of premature ovarian insuf-
ficiency who cannot delay anticancer treatments or who
have already received chemotherapy, or with contraindica-
tions to COS (III, B). Patients with cancer with a high risk
of malignant contamination to the ovaries (e.g. aggressive
hematologic malignancies) should not be considered
eligible for ovarian tissue auto-transplantation (V, B).
Should ovarian cortex tissue banking be performed locally
or should it be centralized?
Embryo and oocyte cryostorage is commonly applied in
several fertility units as part of infertility treatments,
whereas ovarian cortex cryopreservation is applied only
as a technique for fertility preservation in patients at risk
of gonadic exhaustion. Moreover, the effective assessment
of a program of ovarian tissue cryopreservation requires
time: in fact, many years may pass before a sample is
thawed and transplanted. Due to the relatively low number
of procedures requested and the difficulty in evaluating sur-
vival of primordial follicles, the technique of ovarian cortex
cryopreservation should be concentrated to few centers
with the appropriate expertise [10, 11].
Animal experiments showed that the conservation of
ovarian tissue at 4 °C for up to 18 hours causes no mor-
phological damage to preantral follicles; on the contrary,
the storage of ovarian tissue at 20 °C for 18 hours sig-
nificantly reduces the percentage of morphologically
normal follicles [119]. Several reports have demonstrated
the feasibility of harvesting the ovarian cortex in one site
and then transporting it to another site to be frozen. In
specific cooling devices, primordial follicles can survive
to transportation for up to 4–6 hours prior to cryo-
preservation [120, 121]. Pregnancies after ovarian tissue
cryostorage following a transportation for more than
20 hours have also been reported [122].
Centers that perform cryopreservation, storage and
transplantations of ovarian tissue require a connection
with highly specialized laboratories for detecting traces
Table 5 The 10 recommendations drafted by the expert panel
Recommendations
1) Ovarian stimulating drugs with standard treatment protocols may be
administered in subfertile/infertile women without increasing the risk of
developing breast cancer (III, B). The long-term use of clomiphene outside
the current limited indications (i.e. first-line therapy of WHO Group II
anovulatory infertility) should be discouraged because of a possible
increase in breast cancer risk (III, B).
2) Pregnancy in cancer survivors, after adequate treatment and follow up,
should not be discouraged, including among patients with
endocrine-sensitive breast cancer (III, A).
3) All patients with potential interest in keeping their fertility should be
referred to fertility unit for adequate determination of risk of infertility,
chances of future conception and how to proactively preserve it (V, A).
However, some cancer patients will not require the help of a fertility
clinic after cancer treatment (V, B). Since several patient- and treatment-
related factors are associated with the risk of developing infertility, the
oncofertility counseling should be tailored to the individual patient (V, A).
4) In men, sperm cryopreservation is an easily accessible and widely
available option in more than 95 % of patients and should be
encouraged for those who want to preserve fertility (III, A). On the
contrary, from 2 % to 65 % of women undergo one of the available
cryopreservation options: oncologists should discuss with them the
fertility issues and secure proper counseling in appropriate centers prior
to cancer treatment (IV, A).
5) Paucity of data is available on fatherhood after cancer. Although most
of the published data are reassuring, some recent conflicting results
suggest a potential increased risk of birth defects particularly among the
children born closer to a paternal cancer diagnosis, and caution should
be taken in counseling these patients (V, B for discussion with patients);
data on children conceived after ART are too scarce to draw any
conclusion although in the general population, available evidence for
the outcomes of progeny after ART suggests safety of the techniques
themselves (V, B for discussion with patients).
6) The current limited data suggest the safety of a COS in cancer
patients (III, B). “Random-start protocols” can be employed to avoid
delays in anticancer treatment initiation (III, B). LHRHa ovulation
triggering should be adopted in patients at moderate-high risk for OHSS
(I, A). Letrozole (or tamoxifen) should be incorporated in the protocol
for COS in cancer patients with hormone-responsive tumors (III, B).
7) Embryo and oocyte cryopreservation are standard options for fertility
preservation (III, B). Vitrification showed a better performance than slow
freezing (II, B). During oncofertility counseling, patients should be aware
that data on the success of these strategies derive from infertile women
in general and that a different ovarian response to stimulation might be
expected in cancer patients (IV, B).
8) The best candidates for ovarian tissue cryopreservation are prepubertal
girls (III, A). The technique may also be proposed to patients scheduled for
treatments with a high risk of premature ovarian insufficiency who cannot
delay anticancer treatments or who have already received chemotherapy,
or with contraindications to COS (III, B). Patients with cancer with a high
risk of malignant contamination to the ovaries (e.g. aggressive hematologic
malignancies) should not be considered eligible for ovarian tissue
auto-transplantation (V, B).
9) In order to optimize the procedure in terms of both patient management
and cost-effectiveness, the harvesting of the tissue can be performed locally
but subsequent sample freezing and storage centralized (III, B). A
well-organized network between fertility units is required (III, B).
10) Ovarian suppression with the use of LHRHa during chemotherapy
should be considered a reliable strategy to preserve ovarian function
and fertility, at least in breast cancer patients, given the availability of
new data suggesting both the safety and the efficacy of the procedure
have become available (I, A)*.(*CYA, HAA, GBLS and WHW disagree with
this statement, considering the strategy still experimental).
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molecular levels before the grafting. Optimization of freez-
ing methods and cancer cell detection techniques are
other two valid reasons to concentrate the application of
an “experimental technique” in a few referral centers. On
the other hand it would be preferable to organize the har-
vesting of the tissue locally to ensure the access to this
technique to all the eligible patients. Even though some
skills are required to perform an ovarian cortex biopsy
suitable for cryopreservation, any gynecological or fertility
unit may easily acquire them.
Recommendation 9 In order to optimize the procedure
in terms of both patient management and cost-
effectiveness, the harvesting of the tissue can be performed
locally but subsequent sample freezing and storage central-
ized (III, B). A well-organized network between fertility
units is required (III, B).
Should ovarian suppression with LHRHa be proposed as a
reliable strategy to preserve ovarian function and fertility
during chemotherapy?
Ovarian suppression with the use of LHRHa during
chemotherapy is an attractive option to preserve gonadal
function and fertility given the wide availability of such
agents and the advantage of causing no delay in the initi-
ation of anticancer therapies [123]. A total of 10 ran-
domized studies in patients with breast cancer [124–
133], 2 in women with lymphoma [134, 135] and 1 in
ovarian cancer patients [136] have been conducted to
evaluate the efficacy of this strategy: overall, these trials
reported conflicting results. Heterogeneous target popula-
tion and differences in the patient populations, chemo-
therapy regimens used, duration of follow up and study
end-points are the major limitations in comparing these
studies [137]. A total of 12 meta-analyses have attempted
to summarize the data from all these trials [138–149]: the
majority of them showed a potential efficacy of the tech-
nique in reducing the risk of premature ovarian failure,
especially in breast cancer patients.
However, despite this research effort, ovarian suppression
with LHRHa during chemotherapy is still considered an ex-
perimental strategy to preserve fertility by some inter-
national guidelines due to both the uncertainty regarding
the efficacy of this strategy and the absence of data on preg-
nancies and long-term ovarian function [10, 11].
Recently, two large randomized trials evaluating the
efficacy of ovarian suppression with LHRHa during
chemotherapy in breast cancer patients have reported
long-term outcome results [133, 150]. Of note is that in
the POEMS-SWOG S0230 trial only patients with
endocrine-insensitive disease were enrolled, while the
majority of women in the PROMISE-GIM6 study had
hormone receptor-positive breast cancer. Both trials
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dence of chemotherapy-induced POF in patients receiv-
ing LHRHa, one year after the end of chemotherapy in
the PROMISE-GIM6 study (OR = 0.28; P < 0.001) [127]
and two years after the end of chemotherapy in the
POEMS-SWOG S0230 trial (OR = 0.30; P = 0.04) [133].
An increased pregnancy rate was reported by both the
POEMS-SWOG S0230 (OR = 2.45; P = 0.03) [133] and
the PROMISE-GIM6 (age-adjusted HR = 2.40; P = 0.20)
studies [150]. Furthermore, an increased probability for
menstrual resumption at longer follow-up (age-adjusted
HR = 1.48; P = 0.006) was shown in the PROMISE-GIM6
study for patients in the LHRHa arm [150]. A recent
meta-analysis including all the randomized trials con-
ducted in breast cancer patients confirmed the efficacy
of temporary ovarian suppression with LHRHa during
chemotherapy in reducing the risk of treatment-related
premature ovarian failure (OR = 0.36; P < 0.001) and in-
creasing the pregnancy rate (OR = 1.83; P = 0.041) [149].
Recently, the 2015 St. Gallen International Expert
Consensus panel and the National Comprehensive
Cancer Network (NCCN) guidelines have been up-
dated to acknowledge the use of LHRHa in preventing
chemotherapy-induced ovarian failure of hormone re-
ceptor negative breast cancer patients [151, 152]. An
individual patient data meta-analysis of randomized
studies conducted in breast cancer patients is ongoing
with the aim to better elucidate the efficacy of ovarian
suppression with LHRHa as a strategy to protect both
ovarian function and fertility (PROSPERO registration
number: CRD42014015638) [153].
Ovarian suppression with LHRHa during chemother-
apy can be used in combination with other preservation
techniques including cryopreservation strategies, thus
increasing the chance of both fertility and gonadal func-
tion preservation after anti-cancer systemic therapies.
Recommendation 10 Ovarian suppression with the use
of LHRHa during chemotherapy should be considered a
reliable strategy to preserve ovarian function and fertility,
at least in breast cancer patients, given the availability of
new data suggesting both the safety and the efficacy of the
procedure have become available (I, A)*.
(*CYA, HAA, GBLS and WHW disagree with this
statement, considering the strategy still experimental).
Conclusions
Over the last several years, thanks to improvements in
the prognoses of cancer patients, increasing attention
has been given to survivors’ fertility issues. International
guidelines on this topic have been recently updated and
published [10, 11]. However, since then, new data have
become available, and several issues in this field remain
controversial. On the basis of the discussion during themeeting, the expert panel has drafted a total of 10 rec-
ommendations (Table 5).
Although there is a great interest in this field, due to
the lack of large prospective cohort studies and random-
ized studies on these topics, the level of evidence is not
higher than 3 for most of the recommendations highlight-
ing the need of further research efforts. Several registries
and prospective studies are ongoing to evaluate feasibility,
safety and efficacy of fertility preserving strategies in can-
cer patients and encouraging patient participation in these
studies is crucial to acquire more robust conclusions.
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